Oxytocin (catalog: Oxytocin Acetate)
Evidence: A/D — Established Human EvidenceHormone / Fertility
Evidence Snapshot
Regulatory Context
FDA-labeled injectable oxytocin products are used for specified obstetric indications. The catalog wording “Oxytocin Acetate” should be treated as a salt/formulation variant, not as a separate evidence identity without product documentation.
Research Takeaway
Oxytocin (catalog: Oxytocin Acetate) is represented under the canonical identity Oxytocin; catalog and historical names are retained only as aliases.
See all 7 evidence claims →Quick Summary
Oxytocin is an endogenous peptide hormone and an established obstetric medicine. Strong evidence for uterotonic use should not be generalized to intranasal, behavioral, bonding, bodybuilding, or wellness claims.
Mechanism & Research Overview
Oxytocin is an endogenous nonapeptide hormone that activates oxytocin receptors, including receptors on uterine smooth muscle. The approved injectable obstetric context is distinct from intranasal behavioral or social-neuroscience research.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Oxytocin (catalog: Oxytocin Acetate) is represented under the canonical identity Oxytocin; catalog and historical names are retained only as aliases.
Sources: PITOCIN (oxytocin injection) U.S. prescribing information
Supported
Human evidence for Oxytocin (catalog: Oxytocin Acetate) is indication-, route-, and study-specific and must not be generalized beyond the cited populations.
Sources: Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery; Oxytocin bolus plus infusion at elective caesarean section; High-dose versus low-dose oxytocin for augmentation of delayed labour; Water intoxication associated with oxytocin administration
Supported
Uterine hyperstimulation can cause fetal distress, uterine rupture, or other serious obstetric complications.
Sources: Water intoxication associated with oxytocin administration
Supported
FDA-labeled injectable oxytocin products are used for specified obstetric indications. The catalog wording “Oxytocin Acetate” should be treated as a salt/formulation variant, not as a separate evidence identity without product documentation.
Sources: PITOCIN (oxytocin injection) U.S. prescribing information
Supported
A randomized crossover trial in women with sexual dysfunction found improvements with both intranasal oxytocin and placebo, with no significant treatment effect. Laboratory studies in healthy women and men generally did not show reliable improvement in sexual drive, arousal, erection, lubrication, or orgasm. A small couples study found limited context-specific changes but no improvement in classic sexual-function measures. Case reports must not be treated as efficacy evidence.
Sources: Intranasal Oxytocin for Female Sexual Dysfunction; Intranasal Oxytocin in Healthy Women; Intranasal Oxytocin in Healthy Men; Intranasal Oxytocin in Couples
Supported
Larger controlled autism trials have not established a reliable general treatment effect of intranasal oxytocin on core social symptoms, in either adults or children. Small positive studies cannot support broad claims that oxytocin creates trust, love, bonding, empathy, or psychiatric benefit.
Sources: Intranasal Oxytocin for Adult Autism; Intranasal Oxytocin in Pediatric Autism
Supported
Endogenous oxytocin physiology, intravenous or intramuscular obstetric oxytocin, and experimental intranasal oxytocin are not interchangeable evidence categories. Intranasal social, psychiatric, and sexual-function research results are heterogeneous, often small, and sensitive to population, sex, context, dose, and outcome selection. This evidence does not establish oxytocin as a universal 'love' or bonding hormone, does not establish FDA approval for intranasal use, and being endogenous does not make exogenous use risk-free.
Sources: PITOCIN (oxytocin injection) U.S. prescribing information; Intranasal Oxytocin for Female Sexual Dysfunction
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Uterine hyperstimulation can cause fetal distress, uterine rupture, or other serious obstetric complications.Safety Consideration
Prolonged high-dose administration with excess electrolyte-free fluid can cause water intoxication and hyponatremia.Safety Consideration
Evidence from injectable obstetric use does not establish efficacy or safety for intranasal behavioral or wellness uses.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- High-dose versus low-dose oxytocin for augmentation of delayed labour (2019):
- Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery (2018):
- Oxytocin bolus plus infusion at elective caesarean section (2011):
- Water intoxication associated with oxytocin administration (1975):
- Intranasal Oxytocin for Adult Autism ():
- Intranasal Oxytocin for Female Sexual Dysfunction ():
- Intranasal Oxytocin in Couples ():
- Intranasal Oxytocin in Healthy Men ():
- Intranasal Oxytocin in Healthy Women ():
- Intranasal Oxytocin in Pediatric Autism ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| High-dose versus low-dose oxytocin for augmentation of delayed labour | 2019 | Women with delayed labor in a randomized trial | Routine high-dose oxytocin did not show a broad advantage sufficient to outweigh increased hyperstimulation concerns. | Uterine tachysystole and fetal effects are important dose-related outcomes. | |
| Intramuscular versus intravenous oxytocin to prevent postpartum haemorrhage at vaginal delivery | 2018 | Women delivering vaginally in a randomized controlled trial | The trial compared intravenous and intramuscular routes for prevention of postpartum hemorrhage. | Route-dependent hemodynamic and administration considerations require obstetric monitoring. | |
| Oxytocin bolus plus infusion at elective caesarean section | 2011 | Women undergoing elective cesarean delivery | A randomized trial evaluated whether an oxytocin infusion after an initial bolus improved uterine tone and reduced additional uterotonic requirements. | Hemodynamic and uterine effects are route- and dose-dependent. | |
| Water intoxication associated with oxytocin administration | 1975 | Four obstetric cases | The report described water intoxication associated with oxytocin administration and large fluid loads. | Hyponatremia, seizures, and severe neurologic complications can occur in susceptible high-dose/prolonged contexts. | |
| Intranasal Oxytocin for Adult Autism | A multicenter randomized controlled trial of intranasal oxytocin in adults with autism did not establish a reliable general treatment effect on core social symptoms. | ||||
| Intranasal Oxytocin for Female Sexual Dysfunction | A randomized crossover trial in women with sexual dysfunction found improvements with both intranasal oxytocin and placebo, with no significant treatment effect. | ||||
| Intranasal Oxytocin in Couples | A small couples study of intranasal oxytocin found limited context-specific changes but no improvement in classic sexual-function measures. | ||||
| Intranasal Oxytocin in Healthy Men | A laboratory study in healthy men generally did not show reliable improvement in sexual drive, arousal, erection, or orgasm after intranasal oxytocin. | ||||
| Intranasal Oxytocin in Healthy Women | A laboratory study in healthy women generally did not show reliable improvement in sexual drive, arousal, lubrication, or orgasm after intranasal oxytocin. | ||||
| Intranasal Oxytocin in Pediatric Autism | A Phase 2 randomized controlled trial of intranasal oxytocin in pediatric autism did not establish a reliable general treatment effect on core social symptoms. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| PITOCIN (oxytocin injection) U.S. prescribing information | 2024 | FDA-regulated obstetric product labeling | The label describes synthetic oxytocin for specified induction, stimulation, and postpartum uterotonic contexts under medical supervision. | Warnings include uterine hyperstimulation, fetal compromise, cardiovascular effects, and water intoxication with prolonged high-dose infusion. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage | 2013 | Systematic review of randomized trials in the third stage of labor | Prophylactic oxytocin reduced postpartum hemorrhage greater than 500 mL and the need for additional uterotonics compared with placebo or no uterotonic. | Review-level evidence; route, dose, and comparator varied among trials. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-26.
Follow research updates for Oxytocin (catalog: Oxytocin Acetate)
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.